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It is an early Monday morning in January, and Dr. Anna Moreno is preparing to lead the monthly
meeting for the Public Health Risk Sciences Department at the Public Health Agency of Canada
(PHAC). Her role as the Department Manager includes managing weekly meetings and advising
colleagues and upper management when to use a Rapid Risk Assessment (RRA) tool to
respond to any emerging infectious diseases that are relevant to Canadians both domestically
and abroad. Not much has been reported at recent meetings regarding new, emerging, or reemerging infectious diseases posing an urgent or immediate threat to Canadians. Anna decides
to open her email one last time before the meeting to check her news feed and gasps when she
reads the first headline. In response to outbreaks of severe respiratory and gastrointestinal
symptoms within the Americas, and the more than 100 associated deaths over the past month,
the World Health Organization (WHO) has declared an unknown infectious disease a Public
Health Emergency of International Concern (PHEIC).
Statement from the WHO: On January 6, 2020, the Director-General of the WHO, on the
advice of the International Health Regulation Emergency Committee, declared an unknown
emerging infectious respiratory and/or gastrointestinal disease a Public Health Emergency of
International Concern (PHEIC). The Emergency Committee has made the recommendation to
declare a PHEIC due to significant increases in morbidity and mortality related to respiratory
and/or gastrointestinal distress in certain regions of the Americas over a one-month period, with
evidence of high person-to-person transmission. The Director-General advises surrounding
countries to begin surveillance of respiratory and gastrointestinal symptoms and subsequently
implement emergency preparedness responses (see Exhibit 1 for a detailed infectious disease
description).
BACKGROUND
The PHAC is responsible for promoting and protecting the health of Canadians through
leadership, partnership, innovation, and action in public health. The Public Health Risk Sciences
Department focuses specifically on new, emerging, and re-emerging infectious diseases. As
Department Manager, Anna is tasked with responding to global cases of disease emergence
relevant to Canadians and developing an evidence-informed public health response, while being
mindful of available resources, time constraints, and research knowledge gaps. To minimize the
impact of time and resource constraints, it is essential to proactively evaluate and analyze the
risk an infectious disease may pose to society, systems, and individuals. To evaluate this risk,
1This

case uses fictitious identities, department names, and case information.
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the Public Health Risk Sciences Department has created an RRA tool that describes risk in
terms of likelihood and impact. This tool is currently in the preliminary stages of development
and is being tested and refined; however, it is used internally to assess disease risk. This tool
helps estimate risk, reveal the risk drivers, and identify knowledge or data gaps, and it provides
a scientific basis for discussion to help its users gain a shared understanding of the issue. With
the recent PHEIC declaration, it will be Anna’s responsibility to recruit an RRA working group
from her department to contribute to the PHAC’s public health response to the outbreak.
In addition to managing the Public Health Risk Sciences Department at the PHAC, Anna is the
lead of the RRA working group. She is an epidemiologist with experience in infectious disease
management and emergency preparedness. Anna played a large role in the initial development
of the RRA tool over 5 years ago and has since been refining and adapting the tool as
necessary. The RRA working group meets monthly to discuss and monitor new, emerging, or
re-emerging infectious diseases that potentially pose a risk to Canadians. The overall goal of
the working group is to practise a consistent approach to using standardized public health RRA
tools for assessing infectious disease events. The working group functions at the federal level;
therefore, the scope of the project includes infectious diseases relevant to all Canadians
domestically and abroad. The working group aims to produce two possible risk measurements:
the risk to Canadians travelling to countries that have an infectious disease event, and the risk
within Canada after an infectious disease is introduced.
Anna read the WHO statement over and over again. She was aware there had been unusual
increases in respiratory and gastrointestinal illness within the Americas; however, the magnitude
of disease spread and high mortality rate were unexpected. The update included
recommendations to Canada and surrounding countries to increase surveillance and implement
or prepare an appropriate public health response. Anna’s meeting with the working group is in
the next hour, and she will need to have a plan ready to assign tasks and present background
research on the likelihood and impact of such an infectious disease outbreak in Canada. She
will then have to communicate these findings to upper management and the public.
RISK ASSESSMENT
The prevalence of emerging infectious diseases continues to increase with time, remaining a
significant public health challenge exacerbated by changing environmental factors, most notably
by globalization and the climate crisis (Ogden et al., 2017). This upward trend emphasizes the
importance of building our capacity to recognize and respond to identified pathogens to
successfully manage disease occurrence. In the case of an outbreak, time sensitivity makes it
essential to effectively manage and assess this constant influx of information and assess case
reports of infectious diseases that may pose a larger threat to other species (Morgan et al.,
2009).
The European Centre for Disease Prevention and Control defines risk as a combination of the
consequences (impact) of an event or incident (hazard/threat) and the associated likelihood
(probability) of a harmful effect to individuals or populations (European Centre for Disease
Prevention and Control, 2011). There are three main steps to analyzing a risk: hazard
identification, risk assessment, and risk management. These steps are undertaken while
maintaining risk communication throughout the process. Firstly, hazard identification involves
determining the capacity of an agent to cause increases in morbidity and mortality. The second
step—risk assessment—can determine how prepared a region will be for risk management,
emphasizing why it is important to conduct this step promptly and effectively. Lastly, risk
management refers to the decision-making process at the political, social, and economic levels.
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The PHAC defines public health risk assessment more specifically as “the systematic process of
evaluating the potential risk associated with a particular event or issue of health concern, and
the factors that influence it” (Ahmad et al., 2019). This public health risk assessment includes
two main elements: exposure assessment and hazard characterization. Exposure assessment
is designed to quantify the likelihood component of a risk assessment, estimating the chances
of the event occurring within Canada. Hazard characterization is designed to quantify the
severity component of risk assessment, estimating the impact of an event when it occurs. These
outcomes are collectively integrated to arrive at a risk characterization that considers both the
likelihood and severity of the infectious disease in question.
A standard, comprehensive risk assessment can take years to complete. These types of risk
assessments are typically heavily based on existing research and typically completed externally
by academic institutions. A challenge that arises from a standard public health risk assessment
is that the unknown or under-researched diseases will not be assessed in a situation of limited
or low-quality evidence; therefore, the potential risk of new or emerging diseases will not be
captured. Adding the “rapid” component is extremely significant when implementing an RRA
and determining how this risk assessment will function to support and inform public health
decisions and responses.
THE RAPID RISK ASSESSMENT TOOL
The RRA is a core public health function, critical to emergency preparedness and evidenceinformed decision-making within the early stages of an infectious disease event. The RRA tool
serves to estimate the likelihood that an infectious disease will be introduced to Canada and to
estimate the potential impact of this introduction to domestic and travelling Canadians. How
rapid does a rapid risk assessment need to be? Typically, this RRA is conducted in the first 24
to 48 hours of a domestic or international public health event (Ahmad et al., 2019). The outcome
of the RRA can help determine whether a response is indicated, the urgency and magnitude of
this response, and the design of critical measures. Finally, it can help inform further approaches
to managing the event. This ultimately helps reveal the risk drivers, identify public health
priorities, and inform appropriate control measures. There are some clear limitations with any
RRA, including the rapid turnover of evidence and evolving circumstances that may cause the
assessment to become quickly outdated. Additionally, although the RRA commonly captures reemergences of infectious diseases, it may also identify novel diseases that are widely unknown
to science, which introduces difficultly when scientific knowledge is limited. In the case of limited
existing research, the PHAC’s RRA tool relies heavily on obtainable observational data and/or
expert knowledge.
The RRA tool separates risk into international traveller risk and domestic risk, as well as
assesses the likelihood and impact criteria for defining risk within these categories. Below is a
short description of the categories used to assess risk; however, a more detailed version of the
algorithm used is referenced in Exhibits 2 and 3 (Ahmad et al., 2019).
Canadian Traveller Risk (Exhibit 2)
 Likelihood: is exposure abroad likely and are travellers susceptible?
 Impact: is there significant potential for the disease to become severe and widespread
among travellers?
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Domestic Canadian Risk (Exhibit 3)
 Likelihood: is introduction into Canada likely and do conditions exist to support
transmission in Canada?
 Impact: is there significant potential for the disease to become severe and widespread
among Canadians?
Once the RRA is completed by Anna’s team, the Public Health Risk Sciences Department will
communicate the findings to upper management, who will be responsible for disseminating the
information to the public. In this stage of risk communication, it is crucial that public health
representatives minimize panic within the public but also ensure the safety of Canadians.
CASE STUDY: ZIKA VIRUS
This case study is based on real world events.

The need to refine and adapt the RRA was revealed at the PHAC after the re-emergence of Zika
virus disease in Canada in 2016. Zika virus disease was first identified in 1947 when scientists in
Uganda isolated the virus in samples taken from a sentinel rhesus monkey during routine
surveillance for yellow fever in the Zika forest (WHO, 2019). The first human cases were detected
in Uganda and Tanzania five years later; however, the virus was not considered a significant
threat to human health.
Infectious Agent
Zika virus disease is a mosquito-associated flaviviral disease caused by Zika virus. It is related to
other Flaviviridae viruses, including those that cause Japanese encephalitis, West Nile fever,
yellow fever, St. Louis encephalitis, and dengue fever. Aedes aegypti mosquitoes are the primary
vectors of Zika virus; however, they are largely restricted to tropical and subtropical regions
(PHAC, 2019b). Although other Aedes species, specifically Ae. albopictus, are capable of
transmitting Zika virus, these mosquito species do not live in Canada (Infection Prevention and
Control Canada, 2020).
Clinical Presentation
Many people infected with Zika virus are asymptomatic, and severe disease and case fatality
rates are low. Common symptoms of a mild infection are fever, rash, arthralgia, and conjunctivitis.
Cases of Guillain-Barré syndrome, a rare neurological autoimmune disorder that may lead to
nerve damage, have been reported in patients after Zika virus infection. Additionally, Zika virus is
a confirmed cause of microcephaly (having a small head with abnormal brain development) and
other severe fetal neurological complications (PHAC, 2019b).
Outbreaks
Sporadic cases of Zika virus disease in Africa persisted until the first large outbreak was reported
on Yap Island in 2007, with four other islands in the Pacific also reporting disease outbreaks in
2013 and 2014 (WHO, 2019). Until this time, only 14 cases of Zika virus disease were
documented worldwide, whereas now there are thousands of cases. In 2015, the Pan American
Health Organization (PAHO) published an epidemiological update titled “Neurological Syndrome,
Congenital Malformations, and Zika Virus Infection” that highlighted recent increases in GuillainBarré syndrome in several countries of the Americas (PAHO/WHO, 2015). Canada began
surveillance for Zika virus disease in 2015 but only reported 19 cases that year. As of January
21, 2016, Brazil had reported 3,893 microcephaly cases and 49 deaths associated with the virus
(Kindhauser, et al, 2016). Zika virus disease was declared a PHEIC in February 2016 in response
to the significant increase in neurological disorders reported in Brazil, which was mirroring the
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previous outbreak in the Pacific Islands (PAHO/WHO, 2016). In 2016, Canadian cases spiked to
468, compared with the 19 cases reported in 2015. Because pregnancy outcomes are not
reported to public health authorities in Canada, pregnancy and fetal outcomes of Zika-infected
mothers linked to this outbreak are not generally known (PHAC, 2019b).
Transmission
In addition to vector-borne transmission, vertical disease transmission from mother to baby was
established as a route for virus passage after cases of children with microcephaly were born to
Zika-infected mothers in the Americas. There have been no reported cases of transmission. A
new form of transmission was identified in a laboratory-confirmed case in the United States
shortly after Zika virus disease was declared a PHEIC. Zika virus disease was diagnosed in
someone who had no history of travel to regions with Zika virus circulation and who lived in a
region where meteorological conditions could not support such mosquito activity (PAHO/WHO,
2016). This case was confirmed to be sexually transmitted. By the middle of 2016, locally
acquired cases were confirmed by more than 20 countries in the Americas (PAHO/WHO, 2016).
The Rapid Risk Assessment
Given the rapidly evolving Zika virus epidemic, it was clear the efficacy of the RRA needed to be
re-evaluated for future use. When first used for Zika, the tool indicated that the risk to Canadians
was low. However, with an apparent rise in cases in Canada in 2016 and information regarding
sexual transmission, it was clear the risk assessment needed to be repeated. This case depicts
the importance of conducting several RRAs over the course of an epidemic when information and
public health circumstances are evolving rapidly. When comparing the outcomes of the RRA for
Zika virus disease in 2015 with the outcomes in 2016, it is clear how research discovery and
evolving worldwide epidemics can influence the potential risk of emerging diseases to Canadians.
Exposure likelihood and disease impacts must also be reconsidered and re-evaluated over time.
For example, during the Summer Olympic Games in Brazil in 2016, the number of Canadian
travellers visiting regions with Zika virus circulation were predicted to be much higher compared
with the same period in 2015, thereby increasing risk exposure. It is clear that changing
environments, evolving circumstances, and novel research are all dynamic components that will
impact the risk of infectious diseases to Canadians and alter the outcome of risk assessments.
This case study emphasizes the importance of completing multiple risk assessments after the
initial RRA to capture the complexities of evolving information and circumstances.
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THE MEETING
Anna spends the remainder of her morning researching the unknown disease, finding limited
academic evidence and few literature reports about it. With this scarcity of scientific information,
she understands she will need to defer to the expert knowledge of her team members. She
worries that the results of conducting the RRA will mirror the performance of the tool’s
assessment of the Zika virus, which did not indicate a high disease risk to Canadians before the
outbreak in 2016. The working group consists of two epidemiologists, one medical doctor, one
nurse, and one zoonotic disease specialist. Anna notes that when deferring to expert
knowledge, she may encounter difficulties with potential biases associated with their expert
opinions. Anna knows she will have to facilitate a seamless meeting while filtering out the biases
and balancing the perspectives of the experts at the table. With the information currently
available on this unknown emerging infectious disease, how will Anna prioritize expert opinions
on the missing information? Once the assessment is complete, how will Anna communicate
these findings to upper management? How will Anna then advise upper management about
disseminating the findings to the public, given that they are working with limited evidence?
CONCLUSION
Despite the past performance of the algorithm and current knowledge gaps about the disease of
interest, Anna and the RRA working group know they have limited time to begin the assessment
of the new outbreak. The next 24 to 48 hours will be crucial to setting the landscape of PHAC’s
response to the PHEIC and will further contribute to shaping public risk perceptions about an
unknown emerging infectious disease.
NEXT STEPS
Based on the case information, complete the domestic and international risk assessment tools
in Exhibits 2 and 3, using Exhibit 1 for guidance. If information is missing, use the internet to
source scientific evidence to fill the knowledge gaps. Draft a statement that you will
communicate to the public regarding your RRA findings.

80

A Rapid Risk Assessment Tool: Determining the Risk of New/Emerging/
Re-Emerging Infectious Diseases in Canada
EXHIBIT 1
Unknown Emerging Infectious Disease Profile
Statement from the WHO: On January 6, 2020, the Director-General of the WHO, on the
advice of the International Health Regulation Emergency Committee, declared an unknown
emerging infectious respiratory and/or gastrointestinal disease a Public Health Emergency of
International Concern (PHEIC). The Emergency Committee has made the recommendation to
declare a PHEIC because of significant increases in morbidity and mortality related to
respiratory and/or gastrointestinal distress in certain regions of the Americas over a one-month
period, with evidence of high person-to-person transmission. The Director-General advises
surrounding countries to begin surveillance of respiratory and gastrointestinal symptoms and
subsequently implement emergency preparedness responses
Case Information in the Americas




The first case was reported in Brazil on November 30, 2019. A middle-aged woman
reported severe influenza-like symptoms and respiratory distress. In the past seven
days, she ate at the local mall and visited a friend who had two illegal pet birds in her
home.
As of January 6, 2020:
o Case count: 687
o Deaths: 117

Infectious Agent
The infectious agent is thought to be an avian influenza subtype A virus. Although avian viruses
do not normally infect humans, subtypes such as H5N1, H9N2, and H5N6 have caused serious
illnesses in people. The origin of this virus is not known; however, the outbreak began in Brazil
in a person who had been in the house of a friend who had two illegally adopted pet birds.
Transmission Modes
1. Vector-borne: Although the primary vector has not been identified, other avian influenza
viruses have been transmitted from unprotected contact with infected birds or contaminated
surfaces.
2. Airborne/droplet: Human infections with bird flu viruses may occur if the virus enters the
eyes, nose, mouth, or airway. This can commonly occur through droplet transmission.
3. Person-to-person: The person-to-person spread of avian influenza viruses has been rare.
The current cases in Brazil are located within the same region, and a number of cases have
been linked to a potential exposure from an infected member of the same household.
Clinical Presentation
So far, reported illnesses have ranged from mild to severe. Insufficient testing has been done to
identify asymptomatic cases because the infective agent is speculated to be an avian virus but
has yet to be confirmed. Almost all affected people have experienced at least one influenza-like
or respiratory symptom. Symptoms include influenza-like illness (e.g., fever, cough, sore throat,
muscle aches) that is sometimes accompanied by nausea, abdominal pain, diarrhea, vomiting,
and/or severe respiratory illness (e.g., shortness of breath, difficulty breathing, pneumonia,
acute respiratory distress, viral pneumonia, respiratory failure), neurological changes (altered
mental status, seizures), and the involvement of other organ systems (Centers for Disease
Control and Prevention, 2017). Some people fully recover without severe or long-lasting
complications; however, others have long-term respiratory complications or die. Approximately

81

A Rapid Risk Assessment Tool: Determining the Risk of New/Emerging/
Re-Emerging Infectious Diseases in Canada
40% of cases have been categorized as severe and 60% categorized as mild. Severe and fatal
cases are more common in people aged 60 or older or in people who have underlying health
conditions.
Prevention
The best way to prevent infection with avian influenza A viruses is to avoid sources of exposure,
such as direct or close contact with infected poultry or surfaces that may be contaminated.
Antiviral drugs may be able to reduce the severity and length of illness, if taken early enough.
To prevent being exposed to any avian influenza virus, the PHAC (2019a) recommends:






Avoiding contact with birds (alive or dead), including chickens, ducks, and wild birds, and
avoiding high-risk areas such as poultry farms and live animal markets, including areas
where poultry may be slaughtered, when you are travelling to an area where avian
influenza is a concern.
Using alcohol-based hand sanitizer and washing your hands frequently with soap and
warm water for at least 20 seconds.
Practising proper cough and sneeze etiquette, such as covering your mouth and nose.
Monitoring your health regularly; if you develop influenza-like symptoms and you may
have come into contact with the avian virus while travelling, tell border services or a
quarantine officer.

Treatment
Broad spectrum antiviral drugs and supportive therapies have been the gold standard treatment
method so far in Brazil.
Travel
Travel volumes to the Americas are high—Canadians make an estimated 7.3 million annual
visits to the Caribbean, Mexico, and Central and South America. The average age of travellers
is estimated to be between 50 and 60 years of age.
Source: author created
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EXHIBIT 2
Rapid Risk Assessment Tool: Travellers
Algorithm 1: Likelihood of transmission abroad.

Algorithm 2: Impact for Canadian travellers.

These algorithms are in the preliminary stages of development and continue to be revised because they
are currently only used internally at the Public Health Agency of Canada (Vrbova, 2020).

83

A Rapid Risk Assessment Tool: Determining the Risk of New/Emerging/
Re-Emerging Infectious Diseases in Canada
EXHIBIT 3
Rapid Risk Assessment Tool: Domestic
Algorithm 1: Likelihood of transmission in Canada.

Algorithm 2: Impact for Canadian populations and subgroups.

These algorithms are in the preliminary stages of development and continue to be revised because they
are currently only used internally at the Public Health Agency of Canada (Vrbova, 2020.)
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BACKGROUND
The protagonist, Dr. Anna Moreno, is an epidemiologist at the Public Health Agency of Canada
(PHAC), where she manages the Public Health Risk Sciences Department. Her role includes
managing monthly meetings and advising when it is necessary to use the Rapid Risk
Assessment (RRA) tool to conduct an analysis of any emerging infectious disease relevant to
Canada. The case presents a fictitious situation in which a series of outbreaks of an influenzalike infectious disease have occurred in certain regions of the Americas. In response to
outbreaks of severe respiratory and influenza-like symptoms within the Americas and the more
than 100 associated deaths over the past month, the World Health Organization has declared
the unknown infectious disease a Public Health Emergency of International Concern (PHEIC).
Anna has a meeting that morning, and she will need to prepare an approach to create a working
group responsible for conducting an RRA for this unknown disease. Challenges arise because
the existing scientific evidence and literature about the disease is limited and Anna will need to
defer to the expert knowledge of her team while minimizing expert opinion bias. Given the
general standards of RRAs, the assessment should be conducted within the next 24 to 48
hours. Knowing that the outcomes of the risk assessment will set the landscape for the PHAC’s
response to the PHEIC, Anna and her team will need to ensure the assessment is conducted in
a timely and efficient manner. The results of the RRA will be presented to upper management
before being disseminated to the general public. Finally, the case includes a case study, based
on true events, of the initial application of the tool to the 2015 Zika virus disease outbreak.
Although the initial assessment led to the conclusion that Canadians were at minimal risk,
unexpected subsequent Zika outbreaks in 2016 revealed the need to refine and adapt the RRA
tool. This case study emphasizes the importance of completing a risk assessment at multiple
time points throughout the course of a disease to capture the complexities of evolving
information and circumstances.
The pedagogical value of presenting this case is rooted in presenting a real-world situation and
exposing students to the complexities of translating foundational public health practices to social
contexts that do not allow for typical solutions. Although it is necessary to learn concrete
knowledge in a classroom environment, this information serves as a foundation to build on
through experience within the public health field. Being immersed in real-world situations is
imperative for enabling students to visualize how this knowledge may not translate perfectly
during a public health event. This case will complement the focus on emergency preparedness
and monitoring and managerial control mechanisms emphasized in the course MPH 9010Managing Health Services. This level of public health response provides direction and
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recommendations for all sectors in the face of urgent events, such as infectious disease
outbreaks.
OBJECTIVES
Primary Objectives
After reading the case, students should be able to:
1. Explain the need and importance of a rapid risk assessment.
2. Discuss the evolution of infectious disease outbreaks and the impact of research
development on rapid risk assessment.
3. Understand how tools are used to estimate the likelihood of a disease being introduced to
Canada and the potential impact it might have on Canadians.
Secondary Objectives
1. Apply the outcomes of the risk assessment to inform future public health strategies and risk
communication.
2. Develop the ability to suggest improvements for the rapid risk assessment tool and reflect
on challenges faced during its utilization.
DISCUSSION QUESTIONS
Before Class
1. In what situations are rapid risk assessments, compared with standard risk assessments,
most important?
2. What is the main purpose of a rapid risk assessment?
3. What are some limitations to rapid risk assessments?
4. What are some factors that may impact the outcomes of a rapid risk assessment over time?
During Class
1. Review of the Case Study: Zika Virus Disease
 Discuss and brainstorm external factors that are likely to affect risk assessment over time.
An example spider map is provided in the teaching note.
2. Future Challenges for Anna
 Create a bullet point list to outline the challenges and a strategy to overcome them. An
example list is also provided in the teaching note.
3. Risk Communication Class Activity
 Assign one representative from each learning team to present the findings from the rapid
risk assessment and make a statement to the Canadian public who has been waiting to
hear from public health.
4. Debrief/Wrap-Up
 Were there any challenges faced when using the tool?
 Were there any weaknesses to the algorithms?
 Is there anything not included in the algorithm that you believe should be considered?
KEYWORDS
Emergency preparedness; infectious disease; outbreak management; rapid risk assessment;
risk assessment; rapid risk assessment tools; risk communication; Zika virus disease
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